TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients at least 18 years of age, presenting with generalized anxiety disorder (GAD) based on the disease diagnostic criteria. Must suffer from GAD and not from an adjustment disorder or anxiety disorder not otherwise specified. The symptoms of GAD should not be situational in nature.~Exclusion Criteria:~* Any current and primary DSM-IV Axis I diagnosis other than GAD, including:~  * Patients diagnosed with major depressive disorder within the past 6 months; or~ * Patients diagnosed with panic disorder, or post-traumatic stress disorder within the past year; or~ * Patients diagnosed with obsessive-compulsive disorder, bipolar affective disorder, psychosis, factitious disorder, or somatoform disorders during their lifetimes.~* The presence of an Axis II disorder or history of antisocial behavior, which, in the judgement of the investigator, would interfere with compliance with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Consenting patients fulfilling the Poser's criteria for definite MS~2. Age 18-70~3. Male and female~4. EDSS rate 5.5-7.5 (moderate to high disability)~5. Failure to two lines of the currently available registered immunomodulatory treatments for MS. The lack of response to these treatments was determined by either an increase in EDSS or the appearance of at least two relapses of MS during the year prior to inclusion.~Exclusion Criteria:~1. Patients who were treated with cytotoxic medications during the last three months prior to the infusion.~2. Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results.~3. Patients with active infections.~4. Patients with cognitive decline or inability to understand and sign the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Repeated MSCs treatment in MS patients (Type: EXPERIMENTAL): Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA class I-II~2. obtaining written informed consent from the parents~3. aged over 50 years who were undergoing robot- assisted laparoscopic prostatectomy~Exclusion Criteria:~1. eye surgery previously~2. unstable angina or congestive heart failure~3. concomitant eye disease (glaucoma, diabetic retinopathy, cataract, retinal detachment)~4. high intraocular pressure over 30mmHg after screening test.~5. uncontrolled hypertension (diastolic bp\>110mmHg)~6. coagulopathy~7. asthma~8. hepatic failure~9. renal failure(creatinine clearance \< 30 ml/min)~10. drug hyperactivity~11. neurological or psychiatric illnesses~12. mental retardation~13. patients who can't read the consent form due to illiterate or foreigner~14. previous malignant hyperthermia Hx~15. drug medication which interact with muscle relaxant (anti-convulsant, certain antibiotics, magnesium etc)~16. BMI \> 30kg/m2

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Deep neuromuscular blockade (Type: EXPERIMENTAL): Deep neuromuscular blockade
- moderate neuromuscular blockade (Type: ACTIVE_COMPARATOR): moderate neuromuscular blockade

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Managing Chronic Pain in Veterans With Substance Use Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A report of pain of at least moderate or greater over the three months prior to baseline assessment as indicated by an average score of four or greater on the Numeric Rating Scale of pain intensity (NRS-I; Farrar et al. 2001);~* Completion of an intake assessment in the Ann Arbor VA's SUD clinic within the three months prior to baseline assessment. The pain-related inclusion criterion will be used to ensure that participants are experiencing elevated levels of pain and, consequently, are appropriate for pain-related treatment.~Exclusion Criteria:~* Acute suicidality based on responses on the Beck Depression Inventory (BDI) confirmed by in-depth assessment of patient by the research associate;~* Psychiatric condition that precludes participation in outpatient group treatment based on:~  * a Mini-Mental State Examination (MMSE; Folstein et al. 1975) score less than 21,~ * psychiatric hospitalization within the past month, or~ * endorsement of current psychotic symptoms on the Brief Symptom Inventory (BSI; Derogatis 1993) combined with noticeable bizarre thoughts or behavior during the interview;~* Inability to speak and understand English; and~* The inability to give informed, voluntary, written consent.~Decisions about exclusion criteria 1 and 2 will be made using a combination of self-reported symptoms and researcher's judgment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
- Arm 2 (Type: PLACEBO_COMPARATOR): educational supportive group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of birch and/ or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years (verified by a positive skin prick test)~* Patients with need of treatment for their nasal symptoms during the pollen season~Exclusion Criteria:~* Clinical relevant disease or abnormality (past or present) - other than allergic rhinitis~* Symptomatic perennial allergic or non-allergic rhinitis~* A history of asthma

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 12 years of age or older who are able to give written informed consent or who are accompanied by a parent(s)/legal guardian able to provide written informed consent on their behalf.~* Evidence of signed and dated informed consent document(s) indicating that the patient (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study.~* Pain Score ≥ 4 to ≤ 7 as measured using Numerical Rating Scale (NRS) at the time of admission, due to minor trauma.~Exclusion Criteria:~* Life-threatening condition requiring immediate admission in the Operating Room or Intensive Care Unit.~* Presence of any other clinical condition(s) that may, in the opinion of the investigator, impact on the patient's ability to participate in the study, or on the study results, including history of head injury and/or altered consciousness.~* Unable to provide written informed consent.~* Known pregnancy or lactation~* Acute intoxication with drugs or alcohol, based on the judgement of the attending physician.~* Treatment with any analgesic agent within 5 hours prior to presentation to ED (except diclofenac sodium which is prohibited within 8 hours prior to presentation to ED).~* Current ongoing use of analgesics for chronic pain.~* Use of an investigational product within one month prior to presentation to ED.~* Known personal or familial hypersensitivity to fluorinated anaesthetics.~* Known personal or familial history of malignant hyperthermia.~* Clinically significant respiratory depression.~* Use of methoxyflurane in the previous 4 weeks.~* Known pre-existing clinically significant renal or hepatic impairment according to the judgement of the clinician.~* Clinically significant cardiovascular instability.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methoxyflurane (Type: EXPERIMENTAL): None
- Normal Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Clinicians:~* 18 years or older~* Providing IMR individually or in group format at a participating agency~* Willing and able to provide consent~* Willing to complete study measures~* Willing to be audio recorded~Consumers:~* 18 years or older~* Willing and able to provide consent~* Able to complete a brief cognitive screener~* Willing to complete study measures~* Receiving IMR intervention at a participating agency~* Willing to be audio recorded~Exclusion Criteria:~* Individuals younger than 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mini Theta Burst TMS in MDD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 60 years old, inclusive~* Right-handed~* Currently experiencing a major depressive episode (MDD)~* Capacity to give informed consent and follow study procedures~* Command of English language to understand/ respond to written and verbal instructions~Exclusion Criteria:~* MRI contraindications (i.e., metal in body, claustrophobia, etc.)~* TMS contraindications (i.e., seizure disorder)~* Diagnosis of exclusionary psychiatric disorder (i.e., schizophrenia, bipolar)~* Current use of psychiatric medication and unable/ willing to safely withdraw~* Refusal to abstain from alcohol or drugs for duration of study~* Medication use that reduces seizure threshold~* Medication that interferes with blood flow (i.e., opioids, antihypertensive)~* Known neurological disorder or significant disability that interferes with study procedures~* Woman who is pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- All Participants (Type: EXPERIMENTAL): All participants follow the same procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of RRMS according to the Mc Donald criteria(2005)~* 18 to 60 years of age~* Expanded Disability Status Scale (EDSS) \< 6~* Naïve subjects or subjects treated with Rebif® New Formulation for no more than 6 weeks prior to enrollment~* Subjects who have given written informed consent to participate in the study~Exclusion Criteria:~* Primary progressive or secondary progressive MS~* Subjects previously administered IFN beta-1a (including Rebif®) or IFN beta-1b or glatiramer acetate or any other immunomodulatory or immunosuppressive agents or any other MS therapy in the past with the exception of Rebif® New Formulation for no more than 6 weeks prior to enrollment~* Subjects receiving oral or systemic corticosteroids or Adrenocorticotrophic hormone within 30 days of visit 1 (prior to enrolment)~* History of any chronic pain syndrome~* Known allergy to IFN or its excipients~* Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure~* Inadequate liver function, defined by a alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or alkaline phosphatase \> 2 x ULN, or total bilirubin \> 2 x ULN if associated with any elevation of ALT or alkaline phosphatase~* Inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal~* Current or past (within the last 2 years) history of alcohol or drug abuse~* Contra-indications to IFN beta-1a

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have completed participation in 1 of the core studies in adult rheumatoid arthritis.~Exclusion Criteria:~* Treatment with any investigational agent since the last administration of study drug in the core studies.~* Treatment with iv gamma globulin, plasmapheresis, or prosorba column since the last administration of study drug in the core studies.~* Treatment with an anti-TNF or anti-IL1 agent, a T-cell co-stimulation modulator, or any biologic since the last administration of study drug in the core studies.~* Immunization with a live/attenuated vaccine since the last administration of study drug in the core studies.~* Previous treatment with any cell-depleting therapies, including investigational agents.~* Parenteral, intramuscular, or intra-articular corticosteroids within 6 weeks prior to baseline in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus type-2~* Indication to multifactorial risk intervention not in treatment target by means of two out of the following criteria:~  * Low Density Lipoprotein (LDL)-cholesterol \> 120 mg/dl treated or untreated~ * Blood pressure: systolic \>140 mmHg or diastolic \>90 mmHg (office reading, treated or untreated)~ * (Glycated Hemoglobin) HbA1c \> 7.5 % treated or untreated~* Signed informed consent~* Age 45 to 75 years~* Body Mass Index (BMI) \< 35 kg/m2~Exclusion Criteria:~* History of any vascular event except angiography~* Heart failure \> New York Heart Association (NYHA) II~* Serum Creatinine \> 3.0 mg/dl~* Triglycerides \> 400 mg/dl~* Aspartat-Aminotransferase (AST) / Alanin aminotransferase (ALT) \> 3x Upper Limit of Normal (ULN)~* Major psychiatric disorder

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Type 2 Diabetes (Type: None): diabetic subjects, above targets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Type 2 diabetes mellitus~2. HbA1c \>= 7.0%~3. Age \>= 70 years~4. Signed and dated written informed consent~Exclusion criteria:~1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent~2. Impaired hepatic function~3. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or pre-mixed insulins~4. Treatment with anti-obesity drugs

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- linagliptin (Type: EXPERIMENTAL): patients receive linagliptin 5 mg tablets once daily
- placebo (Type: PLACEBO_COMPARATOR): patients receive placebo tablets matching linagliptin 5 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Modified Stem Cells in Stable Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of one completed ischemic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement~* Between 6 and 60 months post-stroke, and having a motor neurological deficit~* No significant further improvement with physical therapy/rehabilitation~* Able and willing to undergo computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) scans of the head~Exclusion Criteria:~* History of more than 1 symptomatic stroke~* History of seizures~* History or presence of any other major neurological disease~* Myocardial infarction within prior 6 mos.~* Known presence of any malignancy except squamous or basal cell carcinoma of the skin~* Participation in any other investigational trial within 4 weeks of initial screening and within 7 weeks of study entry~* Contraindications to head CT, MRI, or PET~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SB623 Implant (2.5M) (Type: EXPERIMENTAL): 2.5 million SB623 cells
- SB623 Implant (5.0M) (Type: EXPERIMENTAL): 5 million SB623 cells
- SB623 Implant (10.0M) (Type: EXPERIMENTAL): 10 million SB623 cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with previously treated Stage III (unresectable)or Stage IV melanoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ipilimumab (MDX-010, BMS-734016) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete